Latest News

  • 23 Sep 2014

    TapImmune CEO Provides Update on Corporate Activity and Prog...

    I am pleased to provide this update to existing shareholders and interested potential shareholders SEATTLE–(BUSINESS WIRE)– TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the...

    more >

  • 18 Sep 2014

    SeeThruEquity Issues Company Update on TapImmune Highlightin...

    SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer New York, NY / ACCESSWIRE / September 18, 2014 /...

    more >